N6-methyladenosine-mediated CELF2 regulates CD44 alternative splicing affecting tumorigenesis via ERAD pathway in pancreatic cancer.

Shihui LaiYan WangTing LiYihong DongYihao LinLiang WangShangeng WengXiang ZhangChengjie Lin

Published in: Cell & bioscience (2022)

This study indicates that N6-methyladenosine-mediated CELF2 promotes AS of CD44, affecting the ERAD pathway and regulating the biological behavior of PC cells. CELF2 is expected to be a new target for targeted-drug development.

Keyphrases

cancer therapy